Patients newly diagnosed with cancer may have a substantially increased short-term risk of arterial thromboembolism, according to a study published today in the Journal of the American College of Cardiology.
Patients with cancer face an increased risk of medical complications.
However, the risk of arterial thromboembolism -- or the blockage of blood flow due to a clot that has come from another part of the body -- in patients with cancer is not well understood.
Researchers found that patients newly diagnosed with cancer faced a considerably increased short-term risk of arterial thromboembolism.
Within six months of diagnosis, more than twice as many patients with cancer had experienced arterial thromboembolism as compared with matched control patients without cancer.
The risks of both heart attack and ischemic stroke were also increased in patients with cancer.
The risk of arterial thromboembolism varied by cancer type, with lung, gastric and pancreatic cancers conferring the highest risk.
Additionally, advanced cancer stage was associated with increased risk, directly relating arterial thromboembolism to overall tumour burden and extent of disease.
According to the authors, these findings raise the question of whether patients with newly diagnosed malignant cancer, particularly those with advanced disease, should be considered for antithrombotic and statin medicines for primary prevention of cardiovascular disease.
They stress that because patients with cancer are also prone to bleeding due to frequent coagulopathy and invasive procedures, carefully designed clinical trials are needed to answer these questions.
Source: American College of Cardiology
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.